FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124321419> ?p ?o ?g. }

• W3124321419 endingPage "782" @default.
• W3124321419 startingPage "772" @default.
• W3124321419 abstract "PurposeOur purpose was to evaluate cosmetic changes after 5-fraction adjuvant stereotactic partial breast irradiation (S-PBI).Methods and MaterialsSeventy-five women with in situ or invasive breast cancer stage 0, I, or II, with tumor size ≤3 cm, were enrolled after lumpectomy in a phase 1 dose escalation trial of S-PBI into cohorts receiving 30, 32.5, 35, 37.5, or 40 Gy in 5 fractions. Before S-PBI, 3 to 4 gold fiducial markers were placed in the lumpectomy cavity for tracking with the Synchrony respiratory tracking system. S-PBI was delivered with a CyberKnife robotic radiosurgery system. Patients and physicians evaluated global cosmesis using the Harvard Breast Cosmesis Scale. Eight independent panelists evaluated digital photography for global cosmesis and 10 subdomains at baseline and follow-up. McNemar tests were used to evaluate change in cosmesis, graded as excellent/good or fair/poor, from baseline to year 3. Wilcoxon signed rank tests were used to evaluate change in subdomains. Cohen’s kappa (κ) statistic was used to estimate interobserver agreement (IOA) between raters, and Fleiss’ κ was used to estimate IOA between panelists.ResultsMedian cosmetic follow-up was 5, 5, 5, 4, and 3 years for the 30, 32.5, 35, 37.5, and 40 Gy cohorts. Most patients reported excellent/good cosmesis at both baseline (86.3%) and year 3 (89.8%). No dose cohort had significantly worsened cosmesis by year 3 on McNemar analysis. No cosmetic subdomain had significant worsening by year 3. IOA was fair for patient-physician (κ = 0.300, P < .001), patient-panel (κ = 0.295, P < .001), physician-panel (κ = 0.256, P < .001), and individual panelists (Fleiss κ = 0.327, P < .001).ConclusionsDose escalation of S-PBI from 30 to 40 Gy in 5 fractions for early stage breast cancer was not associated with a detectable change in cosmesis by year 3. S-PBI is a promising modality for treatment of early stage breast cancer. Our purpose was to evaluate cosmetic changes after 5-fraction adjuvant stereotactic partial breast irradiation (S-PBI). Seventy-five women with in situ or invasive breast cancer stage 0, I, or II, with tumor size ≤3 cm, were enrolled after lumpectomy in a phase 1 dose escalation trial of S-PBI into cohorts receiving 30, 32.5, 35, 37.5, or 40 Gy in 5 fractions. Before S-PBI, 3 to 4 gold fiducial markers were placed in the lumpectomy cavity for tracking with the Synchrony respiratory tracking system. S-PBI was delivered with a CyberKnife robotic radiosurgery system. Patients and physicians evaluated global cosmesis using the Harvard Breast Cosmesis Scale. Eight independent panelists evaluated digital photography for global cosmesis and 10 subdomains at baseline and follow-up. McNemar tests were used to evaluate change in cosmesis, graded as excellent/good or fair/poor, from baseline to year 3. Wilcoxon signed rank tests were used to evaluate change in subdomains. Cohen’s kappa (κ) statistic was used to estimate interobserver agreement (IOA) between raters, and Fleiss’ κ was used to estimate IOA between panelists. Median cosmetic follow-up was 5, 5, 5, 4, and 3 years for the 30, 32.5, 35, 37.5, and 40 Gy cohorts. Most patients reported excellent/good cosmesis at both baseline (86.3%) and year 3 (89.8%). No dose cohort had significantly worsened cosmesis by year 3 on McNemar analysis. No cosmetic subdomain had significant worsening by year 3. IOA was fair for patient-physician (κ = 0.300, P < .001), patient-panel (κ = 0.295, P < .001), physician-panel (κ = 0.256, P < .001), and individual panelists (Fleiss κ = 0.327, P < .001). Dose escalation of S-PBI from 30 to 40 Gy in 5 fractions for early stage breast cancer was not associated with a detectable change in cosmesis by year 3. S-PBI is a promising modality for treatment of early stage breast cancer." @default.
• W3124321419 created "2021-02-01" @default.
• W3124321419 creator A5000962617 @default.
• W3124321419 creator A5002188808 @default.
• W3124321419 creator A5005374383 @default.
• W3124321419 creator A5006188927 @default.
• W3124321419 creator A5008059053 @default.
• W3124321419 creator A5011166582 @default.
• W3124321419 creator A5015178186 @default.
• W3124321419 creator A5015224704 @default.
• W3124321419 creator A5016060008 @default.
• W3124321419 creator A5016216146 @default.
• W3124321419 creator A5017035689 @default.
• W3124321419 creator A5023838874 @default.
• W3124321419 creator A5026905234 @default.
• W3124321419 creator A5029218639 @default.
• W3124321419 creator A5032722626 @default.
• W3124321419 creator A5039485130 @default.
• W3124321419 creator A5050391090 @default.
• W3124321419 creator A5054097443 @default.
• W3124321419 creator A5056023437 @default.
• W3124321419 creator A5059684522 @default.
• W3124321419 creator A5064839560 @default.
• W3124321419 creator A5065173770 @default.
• W3124321419 creator A5068359755 @default.
• W3124321419 creator A5072105170 @default.
• W3124321419 date "2021-07-01" @default.
• W3124321419 modified "2023-10-14" @default.
• W3124321419 title "Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer" @default.
• W3124321419 cites W1965663517 @default.
• W3124321419 cites W2011228946 @default.
• W3124321419 cites W2012013759 @default.
• W3124321419 cites W2015529238 @default.
• W3124321419 cites W2024696278 @default.
• W3124321419 cites W2040350756 @default.
• W3124321419 cites W2047365433 @default.
• W3124321419 cites W2047702653 @default.
• W3124321419 cites W2052577752 @default.
• W3124321419 cites W2067420088 @default.
• W3124321419 cites W2075326409 @default.
• W3124321419 cites W2076018967 @default.
• W3124321419 cites W2079457655 @default.
• W3124321419 cites W2101603546 @default.
• W3124321419 cites W2103608035 @default.
• W3124321419 cites W2115718867 @default.
• W3124321419 cites W2119777918 @default.
• W3124321419 cites W2125007898 @default.
• W3124321419 cites W2130746306 @default.
• W3124321419 cites W2146227526 @default.
• W3124321419 cites W2146522000 @default.
• W3124321419 cites W2150275051 @default.
• W3124321419 cites W2171329552 @default.
• W3124321419 cites W2178502550 @default.
• W3124321419 cites W2275035767 @default.
• W3124321419 cites W2513732897 @default.
• W3124321419 cites W2515936577 @default.
• W3124321419 cites W2523146401 @default.
• W3124321419 cites W2577490265 @default.
• W3124321419 cites W2577994305 @default.
• W3124321419 cites W2740659413 @default.
• W3124321419 cites W2917687760 @default.
• W3124321419 cites W2939539639 @default.
• W3124321419 cites W2968365073 @default.
• W3124321419 cites W2972581225 @default.
• W3124321419 cites W2973050966 @default.
• W3124321419 cites W2975261898 @default.
• W3124321419 cites W2993667428 @default.
• W3124321419 cites W3014602666 @default.
• W3124321419 cites W3016251265 @default.
• W3124321419 cites W3022548009 @default.
• W3124321419 cites W3022558526 @default.
• W3124321419 cites W3067502370 @default.
• W3124321419 cites W3081515379 @default.
• W3124321419 doi "https://doi.org/10.1016/j.ijrobp.2021.01.015" @default.
• W3124321419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33476737" @default.
• W3124321419 hasPublicationYear "2021" @default.
• W3124321419 type Work @default.
• W3124321419 sameAs 3124321419 @default.
• W3124321419 citedByCount "11" @default.
• W3124321419 countsByYear W31243214192022 @default.
• W3124321419 countsByYear W31243214192023 @default.
• W3124321419 crossrefType "journal-article" @default.
• W3124321419 hasAuthorship W3124321419A5000962617 @default.
• W3124321419 hasAuthorship W3124321419A5002188808 @default.
• W3124321419 hasAuthorship W3124321419A5005374383 @default.
• W3124321419 hasAuthorship W3124321419A5006188927 @default.
• W3124321419 hasAuthorship W3124321419A5008059053 @default.
• W3124321419 hasAuthorship W3124321419A5011166582 @default.
• W3124321419 hasAuthorship W3124321419A5015178186 @default.
• W3124321419 hasAuthorship W3124321419A5015224704 @default.
• W3124321419 hasAuthorship W3124321419A5016060008 @default.
• W3124321419 hasAuthorship W3124321419A5016216146 @default.
• W3124321419 hasAuthorship W3124321419A5017035689 @default.
• W3124321419 hasAuthorship W3124321419A5023838874 @default.
• W3124321419 hasAuthorship W3124321419A5026905234 @default.
• W3124321419 hasAuthorship W3124321419A5029218639 @default.
• W3124321419 hasAuthorship W3124321419A5032722626 @default.
• W3124321419 hasAuthorship W3124321419A5039485130 @default.

• next